This is a working overview of lyophilization, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-13 and is reviewed periodically as new material appears.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular weight | Approximately 1025 Da | Calculated from the peptide sequence |
| Appearance | White to off-white powder | Common for lyophilized peptide preparations |
| Solubility | Soluble in water | Also soluble in polar organic solvents |
| Storage temperature | -20 °C or below | Used for long-term retention |
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Stone Cold is a 1991 action film directed by Craig R. Baxley and starring Brian Bosworth, Lance Henriksen and William Forsythe. The film's story centers on a biker gang in Mississippi that tries to assassinate district attorney Brent Whipperton and free Trouble Owens, one of their members who is about to be resentenced to death for the murder of a priest. Hyped as the first major biker film in decades, and boasting the feature debut of controversial American football star Brian Bosworth, it has a particularly convoluted production history and went through many creative and logistical challenges. It was released on May 17, 1991, to mostly negative reviews, and underperformed at the box office. It has since enjoyed a modest reappraisal, with favorable comparisons being made to the more sanitized approach of modern action pictures.
IgE was simultaneously discovered in 1966–67 by two independent groups: Ishizaka's team at the Children's Asthma Research Institute and Hospital in Denver, USA, and by Gunnar Johansson and Hans Bennich in Uppsala, Sweden. Their joint paper was published in April 1969.
This nuclide was long thought to be stable, but in 2003 it was found to be unstable, with a very long half-life of 20.1 billion billion years; it is the last step in the chain before stable thallium-205. Because this bottleneck is so long-lived, very small quantities of the final decay product have been produced, and for most practical purposes bismuth-209 is the final decay product. In the past, during the first few million years of the history of the Solar System, there were more unstable high-mass nuclides in existence, and the four chains were longer, as they included nuclides that have since decayed away. Notably, 244Pu, 237Np, and 247Cm have half-lives over a million years and would have then been bottlenecks higher in the 4n, 4n+1, and 4n+3 chains respectively - 244Pu and 247Cm have been identified as having been present. (There is no nuclide with a half-life over a million years above 238U in the 4n+2 chain.) Today some of these formerly extinct isotopes are again in existence as they have been manufactured. Thus they again take their places in the chain: plutonium-239, used in nuclear weapons, is the major example, decaying to uranium-235 via alpha emission with a half-life 24,500 years. There has also been large-scale production of neptunium-237, resurrecting the extinct fourth chain. The tables below hence start the four decay chains at isotopes of californium with mass numbers from 249 to 252.
Sources: en.wikipedia.org
==== Frailty syndrome ==== In 2017, a small-scale study on individuals 60 years or older with aging frailty showed, after intravenous treatment with Mesenchymal stem cells (MSC) from healthy young donors, significant improvements in physical performance measures. MSC helps with the blockade of inflammation by decreasing it, causing the effects of frailty to reverse.
=== International Food Safety Authorities Network (INFOSAN) === The International Food Safety Authorities Network (INFOSAN) is a joint program of the WHO and FAO. INFOSAN has been connecting national authorities from around the globe since 2004, with the goal of preventing the international spread of contaminated food and foodborne disease and strengthening food safety systems globally. This is done by:
== Career and research == While a graduate student at the University of Iowa, Sherman also worked in the campus library and as a janitor in addition to his research assistant duties. In 1953, while working as a research associate in the university's Department of Urology, Sherman refined a process that had been developed in 1949 by A.S. Parkes and two British scientists, which involved the use of glycerol to preserve animal sperm during freezing and thawing. Combined with the glycerol method, Sherman introduced slow cooling and use of solid carbon dioxide as a refrigerant during storage. Sherman collaborated on these experiments with urologist Dr. Raymond Bunge, who arranged for Sherman to be hired in the urology department and who was affiliated with the university's new fertility clinic, which had opened in early 1952. Bunge and Sherman had met while Sherman was painting the former's house in another side job. In 1953, three patients at the clinic were impregnated using frozen sperm, with Dr. William Keettel, an obstetrician at the fertility clinic, overseeing the patients. The same year, Sherman established the first sperm cryobank in the world in Iowa City to assist these pregnancies. Bunge and Sherman published their findings first in the Proceedings of the Society for Experimental Biology and Medicine and later Nature magazine.
=== Adaptive explanations === Some scholars go as far as to claim that neither insulin resistance, nor obesity really are metabolic disorders per se, but simply adaptive responses to sustained caloric surplus, intended to protect bodily organs from lipotoxicity (unsafe levels of lipids in the bloodstream and tissues): "Obesity should therefore not be regarded as a pathology or disease, but rather as the normal, physiologic response to sustained caloric surplus... As a consequence of the high level of lipid accumulation in insulin target tissues including skeletal muscle and liver, it has been suggested that exclusion of glucose from lipid-laden cells is a compensatory defense against further accumulation of lipogenic substrate." Other prevailing thoughts that insulin resistance can be an evolutionary adaptation include the thrifty gene hypothesis. This hypothesis raises the point that if there is a genetic component to insulin resistance and Type 2 diabetes, these phenotypes should be selected against. Yet, there has been an increase in mean insulin resistance in both the normoglycemic population as well as the diabetic population. J.V. Neel posits that in ancient human ancestors, during periods of heightened famine, genes facilitating increased glucose storage would have conferred an advantage. However, in today's modern environment, this is no longer the case.
Sources: en.wikipedia.org
For big data analytics tools "to enter the public domain, work for the common good and not just for corporate interests, they need to be funded and developed by public organizations." The United Kingdom, Greece, and other national governments have already announced large investments in digital agriculture. Governments can also engage in private-public R&D partnerships to foster smallholder-oriented digital agriculture projects in developing countries. Lastly, digital agriculture technologies, particularly traceability systems, can improve monitoring of environmental compliance, evaluation of subsidy eligibility, etc. Finally, when governments and international undertake complementary investments, they can strengthen the enabling environment for digital agriculture. By improving digital infrastructure, choosing digital agriculture technologies appropriate for the regional context, and investing in human capital/digital skills development, policymakers could support digital agriculture.
Laminin G domain: all laminin alpha chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5), cadherin EGF LAG seven-pass G-type receptors (CELSR1, CELSR2, CELSR3), contactin-associated proteins (CNTNAP1, CNTNAP2, CNTNAP3, CNTNAP3B, CNTNAP4, CNTNAP5), some collagens (COL5A1, COL5A3, COL9A1, COL11A1, COL11A2, COL12A1, COL14A1, COL15A1, COL16A1, COL18A1, COL19A1, COL20A1, COL21A1, COL22A1, COL24A1, COL27A1), crumbs homologs 1 and 2 (CRB1, CRB2), fat homologs (FAT1, FAT2, FAT3, FAT4), NEL-like proteins (NELL1, NELL2), neurexins (NRXN1, NRXN2, NRXN3), slit homologs (SLIT1, SLIT2, SLIT3), thrombospondins (THBS1, THBS2, THBS3, THBS4, TSPEAR), agrin (AGRIN), chondroitin sulfate proteoglycan 4 (CSPG4), eyes shut homolog (EYS), growth arrest-specific protein 6 (GAS6), perlecan (HSPG2), pikachurin (EGFLAM), protein S (PROS1), sex hormone-binding globulin (SHBG) and usherin (USH2A) Laminin N-terminal (domain VI): most laminin chains (LAMA1, LAMA2, LAMA3, LAMA5, LAMB1, LAMB2, LAMB3, LAMB4, LAMC1, LAMC3), most netrins (NTN1, NTN3, NTN4, NTNG1, NTNG2), and usherin (USH2A)
oxidizing agent Also oxidant, oxidizer, or electron acceptor. 1. A chemical species that gains or accepts one or more electrons from another species, called the reducing agent, in a redox reaction, thereby causing the oxidation of the other species and in turn being itself reduced. The oxidizing agent's oxidation state decreases, while the reducing agent's increases. 2. A chemical species that transfers strongly electronegative atoms, usually oxygen, to a substrate.
Sources: en.wikipedia.org
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.
PDE5 inhibitors act on peripheral vascular tissue to increase blood flow. Bremelanotide acts centrally on melanocortin receptors and is associated with dopaminergic pathways. The two approaches therefore target different parts of the arousal response.
It is a synthetic peptide analog rather than a hormone produced by the body. Alpha-melanocyte-stimulating hormone is the natural peptide it resembles. The two share structural features but are distinct molecules.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.